Last Updated : April 23, 2025
Details
FilesGeneric Name:
pembrolizumab
Project Status:
Active
Therapeutic Area:
Cervical cancer
Manufacturer:
Merck Canada Inc.
Call for patient/clinician input open:
Brand Name:
Keytruda
Project Line:
Reimbursement Review
Project Number:
PC0411-000
Call for patient/clinician input closed:
Tumour Type:
Gynecology
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Pembrolizumab for the treatment of adult patients with FIGO 2014 Stage III-IVA cervical cancer, in combination with chemoradiotherapy (CRT).
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Pembrolizumab for the treatment of adult patients with FIGO 2014 Stage III-IVA cervical cancer, in combination with chemoradiotherapy (CRT).
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | February 10, 2025 |
|---|---|
| Call for patient/clinician input closed | April 07, 2025 |
| Submission received | March 25, 2025 |
| Submission accepted | April 08, 2025 |
| Review initiated | April 09, 2025 |
| Draft CADTH review report(s) provided to sponsor for comment | June 25, 2025 |
| Deadline for sponsors comments | July 07, 2025 |
| CDA-AMC review report(s) and responses to comments provided to sponsor | July 31, 2025 |
| Expert committee meeting (initial) | August 13, 2025 |
| Draft recommendation issued to sponsor | August 25, 2025 To August 27, 2025 |
| Draft recommendation posted for stakeholder feedback | September 04, 2025 |
| End of feedback period | September 18, 2025 |
Files
Last Updated : April 23, 2025